Precision BioSciences

Precision BioSciences

Precision BioSciences

Precision BioSciences utilizes its proprietary ARCUS Genome Editing method to overcome cancers, cure genetic diseases, and enable development of safer food.
Raised
$236.4M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$126,400,000
IPO - 2019
Team Size
1–10
Employees
$126,400,000 IPO
PE HUB

VC-backed BioSciences goes public

$110,000,000 Venture capital (Series B)
FinSMEs

Precision BioSciences Raises $110M in Series B Funding

Funding